Why the study?
No-reflow during primary PCI for STEMI is associated with poor clinical outcomes and mortality, prompting investigation into whether intracoronary adenosine prevents this phenomenon.
Does intracoronary adenosine before stenting prevent the no-reflow phenomenon in patients with STEMI undergoing primary PCI?
Does intracoronary adenosine before stenting prevent the no-reflow phenomenon in patients with STEMI undergoing primary PCI?
Answers are grounded in this paper and cite their sources.
Intracoronary adenosine administered prior to stenting significantly reduces the incidence of angiographic no-reflow in patients with STEMI undergoing primary PCI.
Objectives: No-reflow phenomenon during the primary percutaneous intervention (PCI) for ST-elevation myocardial infarction (STEMI) is accompanied by a poor clinical outcome and mortality. We aimed to determine the effect of intracoronary adenosine in preventing the no-reflow phenomenon, as detected by three different methods, in patients who underwent primary (PCI). Design. In this single-blinded randomized controlled trial, patients with acute STEMI who presented to our center and underwent primary PCI were randomized to the intervention group who received intracoronary adenosine before stenting or the control group who received the standard treatment. No-reflow phenomenon was detected using thrombolysis in myocardial infarction (TIMI) flow grade, TIMI frame count, and myocardial blush grade (MBG). The incidence of the no-reflow phenomenon was then compared between the intervention and control groups. Results. The adenosine group consisted of 110 patients (age = 57 ± 11 years; 92 (84%) male) while 118 patients were in the control group (age = 59 ± 12 years; 89 (75%) male). There was no difference between the study groups in baseline characteristics. The frequency of no-reflow phenomenon was lower in the adenosine group as assessed by TIMI flow grade (15 [14%] vs. 41 [35%]), MBG (23 [21%] vs. 63 [53%]) and TIMI frame count (16 [14%] vs. 50 [42%]) (p < .001 for all). This effect remained significant after adjustment for confounding variables. Conclusion. Intracoronary adenosine could effectively prevent the no-reflow phenomenon in STEMI patients who underwent primary PCI.
No takes yet. Share an insight, caveat, or question.
Sadeghian et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: